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Regular Sunscreen Use Is a Cost-Effective Approach
to Skin Cancer Prevention in Subtropical Settings
Louisa G. Gordon1,3, Paul A. Scuffham2,3, Jolieke C. van der Pols1, Penelope McBride1, Gail M. Williams4
and Ade`le C. Green1,3
In many developed countries, total costs to health systems for cutaneous basal cell carcinomas (BCCs) and
squamous cell carcinomas (SCCs) are among the highest of all cancers, yet the investment value of preventive
measures remains unknown. Using primary data from a randomized controlled trial, we estimated the cost-
effectiveness of a skin cancer prevention initiative based on regular sunscreen use. Compared with usual
practice (discretionary use), the sunscreen intervention cost an additional US$106,449 (2007) to prevent 11 BCCs,
24 SCCs, and 838 actinic keratoses among 812 residents over 5 years. These health outcomes required an annual
average investment of US$0.74 per person and saved the Australian government a total of US$88,203 in health-
care costs over the same period. Such community-based interventions promoting regular sunscreen use among
Caucasians in subtropical settings can prevent skin cancer and related skin tumors in practical ways and with
great cost efficiency.
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INTRODUCTION
In populations with large percentages of people of European
descent, basal cell carcinomas (BCCs) and squamous cell
carcinomas (SCCs) of the skin impose a substantial burden in
human and economic terms. Because of the negligible
mortality compared with other cancers, their high incidence
rates and attendant costs tend to be overlooked. In the United
States alone, Medicare spends US$13 billion each year on
skin cancer treatment. Added to this are the costs of
associated skin tumors such as actinic keratoses (AKs), which
are highly prevalent—around 6–25% in the United Kingdom
and the United States (Holmes et al., 2007) and 40–60% in
Australia (Darlington et al., 2003; Holmes et al., 2007)—and
among the strongest predictors of skin cancer (Darlington
et al., 2003).
Given that UV radiation is the major environmental cause
of skin cancers (International Agency for Cancer Research,
1992), they are preventable by sun-protective behaviors. In
combination with other primary sun-avoidance measures,
such as shade and sun-protective clothing, the use of broad-
spectrum sunscreens is an effective adjunct measure. The
safety and efficacy of sunscreens in protecting human skin
from squamous tumors have been established (Thompson
et al., 1993; Green et al., 1999). Because of their central role
in skin cancer prevention, sunscreens are unanimously
recommended by health authorities in the United States (US
Preventive Services Task Force, 2001), the United Kingdom
(National Radiation Protection Board UK, 2008), and
Australia (Cancer Council Australia and Australasian College
of Dermatologists, 2007).
Using data from a community-based randomized con-
trolled trial (Green et al., 1999), we evaluated actual use of
health-care resources, costs, and health outcomes of BCC and
SCC prevention in order to address the question of whether
an intervention for skin cancer prevention that promotes the
daily application of sunscreen among Caucasians in a sunny
environment is a sound economic investment. From a
societal perspective, a cost-effectiveness analysis was under-
taken using direct health-outcomes data obtained when
individuals from a Queensland community took part in a
single randomized controlled trial (Green et al., 1999) over a
5-year period.
RESULTS
Of the 1,621 residents enrolled, 1,383 (85%) remained active
participants at the end of the trial. Participants who withdrew
were younger on average than ongoing participants (47 vs. 49
years, respectively) but otherwise similar (Green et al., 1999).
From January 1993 to December 1997 inclusive, 155 (10%)
participants developed 277 new histologically confirmed skin
cancers. The occurrence of 11 fewer BCCs and 24 fewer
SCCs among the participants in the daily-sunscreen arm
compared with those in the usual-practice arm (Table 1) was
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attributed to sunscreen intervention. Similarly, on the basis of
intention-to-treat analyses, an estimated 838 AKs were
prevented in the daily-sunscreen arm from 1992 to 1996
(Darlington et al., 2003) (Table 2).
From a societal perspective, the net total cost over 5 years
for the daily-sunscreen intervention group was US$329,149
versus $222,700 for the usual-practice group (Table 3). The
cost for the intervention group was partially offset by reduced
medical care costs of $88,203 for avoided SCC, BCC, and AK
(assuming 50% of AKs were treated). These net costs
translated into $405 versus $275 per person for the
intervention and usual-practice groups, respectively. From
the perspective of the Australian government (which funds
the vast majority of health care in such cases), the net cost
over 5 years was $50,103 for the daily-sunscreen group
versus $138,306 for the usual-practice group; thus, cost
savings, fewer skin cancers, and fewer AKs were attributed to
the regular use of sunscreen.
Combining skin cancer and cost outcomes, the incre-
mental cost per skin cancer prevented over 5 years was
US$3,041 from a societal viewpoint, but it represented a
savings to the government (Table 3). This equated to an
investment of $3.72 per person over 5 years (or $0.74
annually). Cost-effectiveness ratios were sensitive to the
inclusion of conservative cost estimates for AKs and to the
proportion of AKs treated (50% in the base analysis). If 100%
Table 1. Incidence of histologically confirmed BCCs and SCCs on the head, neck, arms, and hands, from 1993 to
1997, by randomized sunscreen treatment group
Persons affected
with skin cancer
Daily sunscreen
group
Discretionary
sunscreen group Total
Difference (persons
with fewer cancers)
Rate ratio
(95% CI)1
BCC 59 57 116 2 1.04 (0.72–1.49)
SCC 23 34 57 11 0.68 (0.40–1.15)
Total 79 76 1552 9
Counts of skin cancers
Difference (cancers
prevented)
BCC 94 105 199 11 0.87 (0.56–1.34)
SCC 27 51 78 24 0.50 (0.27–0.92)3
Total 121 156 277 35
BCC, basal cell carcinoma; CI, confidence intervals; SCC, squamous cell carcinomas.
1Rate ratios compared counts of skin cancers in the intervention group with those in the usual practice group.
218 persons affected with cancer had both BCC and SCC, and are not double-counted here.
3Difference was statistically significant, P=0.03.
Table 2. Number of prevalent actinic keratoses (AKs) prevented, attributable to daily sunscreen use, and estimated
cost-savings (US$ 2007) for avoided medical treatment
Management2
Rate ratio
(95% CI)
Participants in daily
sunscreen group
Estimated no. AKs prevented
from daily sunscreen use1
50% of AKs
treated
Physician
visits ($)
Cryotherapy
($)
Topical
cream ($)
Total cost
saving ($)
1994–1992 0.78 (0.64–0.96)1 806 806 403 27,315 31,438 2,306 61,059
1996–1994 0.94 (0.75–1.19)1 797 166 83 5,618 6,466 474 12,558
Total 838 486 32,933 37,904 2,781 73,617
CI, confidence interval.
1On the basis of Darlington et al. (2003), which compares rates of prevalent AKs on sunscreen applied sites in the intervention group relative to the usual
practice group. These results found a 24% reduction during 2-year period 1992–1994 or an equivalent of 1 AK prevented per person, 5% reduction during
1994–1996 or an equivalent of 0.208 prevented per person. Models were adjusted for age, sex, smoking, eye color, hair color, sunburn propensity, previous
history of skin cancer, and occupational exposure.
2Treatment estimates; number of AKs treated 50% (authors assumption), average physician visits per AK=2.87 (Streeton et al., 2006), estimated 95%
cryotherapy & 5% topical creams (Rosen and Studniberg, 2003). Medicare items and unit costs are listed in the supplementary file.
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of the AKs prevented by sunscreen use had otherwise been
treated, the incremental annual cost per cancer prevented
would have dropped to $1.15 per person from $3.72; if 25%
of prevented AKs had been treated, the ratio would have risen
to $5.02 per person (Table 4). On the other hand, in all
sensitivity analyses, the government’s cost-saving position
was preserved. The cost-effectiveness ratios changed margin-
ally when base ratios were recalculated using upper and
lower 95% confidence interval limits of bootstrapped mean
estimates for participant sunscreen application time and
purchases as well as the time and expense of physician visits
(Table 4). The results of the probabilistic sensitivity analyses,
based on 5,000 simulated incremental cost and incremental
effect pairings, showed a mean incremental cost-effective-
ness ratio of $3.72 within a wide 95% confidence interval
range (from cost saving to $29.52 per person: 99% resulted in
better outcomes (cancers prevented) and 8.6% were cost
saving) (Figure 1). The wide interval was driven by the large
possible variation in medical costs.
DISCUSSION
This economic evaluation of an intervention promoting
sunscreen as a means of preventing skin cancer showed that
the intervention saved the government money but imposed a
small cost on society as a whole (health provider, govern-
ments, and participants) for these improved health outcomes.
If health providers, governments, and individuals were
collectively willing to pay and contribute to preventing skin
cancer, this sunscreen initiative would cost society an outlay
of US$3,041 per skin cancer prevented over a 5-year period,
or $0.74 per person annually. Given that this investment is
a fraction of what individuals in developed nations alone
pay for cosmetic skin-care products, this expense seems
extremely worthwhile. For governments in a publicly funded
health system that incur the cost of skin cancer medicine, this
intervention yielded considerable cost savings within 5 years
under a range of cost scenarios.
Our cost-effectiveness ratios compare favorably with those
for other primary prevention initiatives currently approved in
Australia, even considering the upper 95% confidence limit
of $29.52 per person (rather than the mean of $3.72) from our
probabilistic sensitivity analyses. For example, the estimated
cost of Gardasil (CSL, Sydney, Australia), the human papil-
lomavirus vaccine for preventing cervical cancer, began at
around US$360 per dose (Department of Health and Ageing
PBAC, 2006), and for the Rotarix vaccine (GlaxoSmithKline,
Boronia, Australia) against rotavirus gastroenteritis, the cost
was around US$72 per dose (Department of Health and
Ageing PBAC, 2006). Furthermore, there are an estimated
137,600 new cases and 410 deaths from SCC each year in
Australia (Australian Institute of Health and Welfare and
Cancer Australia, 2008), and if, through the use of sunscreen,
a quarter of all new cases could be prevented over 5 years
(Green et al., 1999), then up to 19 deaths could potentially be
prevented each year with regular sunscreen use in Australia.
High proportions of all skin cancers in the United
Kingdom and Australia and around 50% in the United States
are managed by primary care physicians in office-based
settings. This explains the relatively low cost of managing
individual tumors, estimated at a mean US$500 (±$487) per
skin cancer episode (Chen et al., 2001); when managed in
hospital or ambulatory surgical rooms, these costs can be up
to 10 times higher (Chen et al., 2006). Although skin cancers
treated outside primary care were not included, one in five
persons with skin cancer in our sample would need to have
been treated as an inpatient to exceed the upper confidence
Table 3. Costs and skin cancers prevented in the randomized daily and discretionary sunscreen treatment groups,
from 1992 to 1996, from the government and societal perspectives (US$ 2007)
Cost type1
Daily sunscreen
use (n=812)
Discretionary
sunscreen use
(n=809)
(A) Provider costs (salaries, office, consumables, sunscreen) $145,632
(B) Imputed costs for voluntary contributions (unpaid staff (dermatologists, other staff, rental)) $53,032
(C) Participant costs (time to attend skin exam, apply sunscreen, visit doctor, out-of-pocket costs for doctors) $80,382 $84,394
(D) Government-provided health care costs for treatment of skin cancers and AKs $50,103 $138,306
Net government costs (D) $50,103 $138,306
Net societal costs (A+B+C+D) $329,149 $222,700
Incremental costs—government viewpoint Cost saving
Incremental costs—societal viewpoint $106,449
Total skin cancers 121 156
Skin cancers prevented 35
Incremental cost per skin cancer prevented (over 5 years)—government viewpoint Cost saving
Incremental cost per skin cancer prevented (over 5 years)—societal viewpoint $3,041
AK, actinic keratoses.
1Detailed information on resource measurement, unit costs, quantities, valuation, and analysis details are available in the supplementary file.
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limit of medical costs in our sensitivity analysis on the basis of
hospital costs for skin procedures. Thus, our medical costs are
likely to be underestimated not only because of excluded
inpatient costs but also because of our omission of the costs
of treatment morbidity (NHMRC National Health and
Medical Research Council, 2003), as well as because of
additional costs of other common conditions avoidable
through sunscreen use, such as photoaging (Stern, 2004).
Our study used primary data from a rigorous intervention
study (Green et al., 1999; Darlington et al., 2003) with a
‘‘usual practice’’ comparator along with high-quality clinical
data collected over the study period. Although 15% of the
participants were not active for the duration, their health
outcomes would not have materially changed the results,
given their similarity to the overall sample (Green et al.,
1999)). On the other hand, it was not possible to precisely
measure total AKs because of the extremely high prevalence
rates coupled with high rates of spontaneous regression (Frost
et al., 2000). However, their importance as strong predictors
of skin cancer risk is well known, especially SCC (Marks
et al., 1988; Frost et al., 1994). The paucity of evidence about
AK treatment patterns led to our conservative estimation in
costs, although sensitivity testing showed their notable
potential to alter cost-effectiveness ratios. Even with the
exclusion of AK costs, however, the sunscreen intervention
remained cost saving to the government. Our AK cost
estimates emphasize the high level of health resources that
AKs consume when they are managed like skin cancers (for
example, with cryotherapy, topical creams, and periodic
clinical visits).
We conclude that year-round regular sunscreen use for the
prevention of skin cancers produces cost savings for health-
care providers in Australia. Given the growing burden of
costs for skin cancer treatment in the Northern Hemisphere, it
seems likely that the fair-skinned populations of the United
States and Europe could also benefit from cost savings were
sunscreen to be regularly used during summer or during
leisure time spent in subtropical climates.
MATERIALS AND METHODS
The Nambour Skin Cancer Prevention Trial investigated the
effectiveness of daily application of sunscreen (‘‘the intervention’’)
versus the usual discretionary use of sunscreen (‘‘usual practice’’)
(Green et al., 1999). The trial was conducted from 1992 to 1996
among a random sample of the residents of the township of
Nambour, Queensland. Full details of methods (Green et al., 1994),
a participant flow chart, and key findings (Green et al., 1994, 1999)
have previously been published. A total of 812 participants
randomized to the sunscreen intervention were supplied with a
water-resistant, broad-spectrum sunscreen with a sun protection
factor of 15þ . They were asked to apply it daily to the head, neck,
arms, and hands, and application habits were reinforced by study
nurses via a quarterly contact. Ethical approval was obtained from
the Human Ethics Committee of the Queensland Institute of Medical
Research, and informed written consent was provided by all
Table 4. Results of one-way sensitivity analyses1 on
key costs: societal perspective (US$ 2007)
Incremental cost-
effectiveness
ratio (mean per
person)
Base analysis 3.72
Costs involved in skin cancer misdiagnoses
(positive predictive value)
0.60 3.62
0.802 3.79
Medical costs ($) Low 3.81
High3 0.33
Time to visit a GP ($) Low 3.79
High 3.70
Time to apply sunscreen ($) Low 3.77
High 3.66
Sunscreen purchases ($) Low 3.52
High 3.93
Out-of-pockets for GP visit ($) Low 3.77
High 3.70
Proportion of AKs treated 0% 6.31
25% 5.02
100% 1.15
GP, general practitioner.
1Low and high estimates are the lower and upper 95% confidence
intervals from bootstrapped mean results with the exception of sunscreen
purchases that were tested over a 20% higher and lower cost.
2Includes the scenario of higher accuracy and less resource use in
experienced or specialist doctors.
3Includes the scenario of higher costs of skin cancers treated in hospitals.
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Figure 1. Results of probabilistic sensitivity analyses with 95% confidence
ellipse. Incremental cost ¼ cost of daily application minus cost of
discretionary application (mean per person); incremental cancers prevented
¼ cancers in the discretionary group minus those in the daily-sunscreen
group. The 95% confidence ellipse is based on 5,000 Monte Carlo
simulations with binomial distributions assigned for skin cancers prevented,
gamma distributions for cost variables, and normal distribution for positive
predictor value estimates.
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participants. The study was conducted according to the Declaration
of Helsinki Principles.
Skin cancer ascertainment
All participants received a full skin examination by a dermatologist
unaware of treatment allocation, at the start (1992), midpoint (1994),
and completion (1996) of the trial. Interim skin cancers were
ascertained by self-report and/or physicians’ notifications, with
medical record verification. Only histologically confirmed skin
cancers on the head, neck, arms, and hands (‘‘sunscreen sites’’ under
the protocol) were included in our analysis. Cancers diagnosed
during 1992 were excluded a priori, as no beneficial effect of
sunscreen was expected in year 1, given the latent period of skin
tumors in humans; similarly, cancers diagnosed during 1997 were
included to account for the latent effects of the sunscreen
intervention immediately after trial cessation.
Estimation of resources and costs
Because a wider societal perspective was taken, the assessed costs
included those incurred by the program provider, community
supporters, the participants, and the Australian government (through
Medicare Australia, which bears the direct costs of treatment). The
trial was conducted within the context of a large, publicly funded
research program. Research-driven costs were identified and
excluded from the resources for the preventive intervention. Specific
details of measurement, valuation methods, and sources used to
quantify resource use are available online in a Supplementary file.
We also accounted for the avoided costs of AKs, the skin-cancer-
related secondary outcome of the sunscreen intervention (Darlington
et al., 2003), using published Nambour Trial outcome data for AKs
(Darlington et al., 2003). Because it is not feasible to track treatment
pathways for individual AKs and the precise proportion of AKs
treated (as opposed to monitored) in Australian primary care seems
unknown and could vary greatly, we assumed an average treatment
rate of AKs of 50% and tested this assumption in sensitivity analyses.
Meanwhile, usual modes of AK treatment were ascertained by
searching all published Australian studies reporting primary care
management of actinic skin tumors (Raasch, 1999; NHMRC
National Health and Medical Research Council, 2003; Rosen and
Studniberg, 2003; Streeton et al., 2006). Medical services were
valued using Medicare fees, which represent the cost to the
Australian government that is reimbursed to physicians through
Medicare Australia. Using diagnosis dates, we also accounted for
cost efficiencies relating to physician visits, treatment, and pathology
when a person seemed to have had several cancers treated
simultaneously (Richmond-Sinclair et al., 2008). In addition,
adjustments to medical costs were made to account for the
percentage of benign lesions that would have been treated
provisionally as cancers. These adjustments were made on the basis
of a positive predictive value of 70% (Youl et al., 2007) and were
further tested by varying the positive predictive value between 60
and 80% in analyses.
Analysis
Using intention-to-treat analyses, the numbers of BCCs and SCCs in
the intervention and usual-practice arms were compared and tested
for statistically significant group differences using negative binomial
regression, and a comparison of persons affected with cancer in each
arm was carried out using Poisson regression. For AKs, ratios of
successive counts of prevalent AKs indicated the rate of change in
AK acquisition in each sunscreen treatment arm (Darlington et al.,
2003). Statistically significant differences were tested using negative
binomial regression. Tests were two-sided and results were
considered statistically significant when Po0.05.
Resources were identified and measured for the various time
periods, and year-2007 Australian dollars were applied. Costs are
presented in year-2007 US dollars (converted at AU$ 1 ¼ US$ 0.72,
using Organization for Economic Cooperation and Development
purchasing-power parities). The analysis did not involve future costs
or benefits (because it was retrospective, with the costs and out-
comes already known), and therefore discounting was not applied.
Individual-level data relating to sunscreen purchase and application
time, physician-visit time and expense, and other medical costs were
right skewed; we therefore obtained bootstrapped mean costs per
participant using 1,000 bootstrapped samples and the bias-corrected
approach (Briggs, 2001). Wald’s test was used to detect significant
group differences with 95% confidence intervals.
The measure of benefit for this economic evaluation was ‘‘skin
cancers prevented.’’ Final cost and health outcome data were
combined into incremental cost–effectiveness ratios, interpreted as
the additional cost for preventing each new skin cancer in the
intervention group. To address the uncertainty in our estimations,
one-way and probabilistic sensitivity analyses were undertaken to
test the stability of the base results when individual parameter values
were varied (Briggs, 2001). In the probabilistic sensitivity analyses,
all cost variables, the probability of skin cancer, and positive
predictor values were simultaneously analyzed using 5,000 Monte
Carlo simulations to assess the variation to the base results. After the
actual patient-level data distributions, gamma distributions were
assigned for cost variables, binomial distributions for skin cancer
counts, and normal distributions for positive predictor estimates
(Youl et al., 2007) across the two groups. Data were analyzed using
STATA/SE V9 (StatCorp., College Station, Texas) and TreeAge Pro
2008 (TreeAge Software Inc, Williamstown, MA).
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